Related Experiment Video
Updated: Apr 30, 2026

Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications
Published on: June 29, 2020
Crimean Congo hemorrhagic fever in Hazara division
Insights
Crimean-Congo Hemorrhagic Fever (CCHF) is a deadly tick-borne disease in Pakistan. Early evaluation for fever and low platelets is crucial, and oral Ribavirin shows promise for treating CCHF.
Area of Science:
- Infectious Diseases
- Virology
- Public Health
Background:
- Crimean-Congo Hemorrhagic Fever (CCHF) is an endemic, highly fatal zoonotic disease in Pakistan.
- The study addresses the need for focus on this emerging disease due to numerous outbreaks and sporadic cases.
Purpose of the Study:
- To describe the clinical features, treatment, and outcomes of CCHF cases during an outbreak in Hazara division.
- To highlight the significance of CCHF as a fatal emerging disease.
Main Methods:
- Study conducted at Ayub Teaching Hospital, Abbottabad over three months.
- Included patients with fever and platelet count < 50,000/mm3.
- CCHF virus detection via blood samples; supportive care with fresh frozen plasma and oral Ribavirin administered.
Main Results:
- Eighty-eight patients with fever and thrombocytopenia were analyzed.
- Eight patients tested positive for CCHF.
- Six patients recovered fully, one died, and one left against medical advice.
Conclusions:
- Suspicion and evaluation for CCHF are recommended for all patients with acute fever and thrombocytopenia.
- Oral Ribavirin demonstrated safety and effectiveness in CCHF treatment.
Background:
Crimean-Congo Hemorrhagic fever (CCHF) is endemic in certain areas of Pakistan with 14 outbreaks in addition to many sporadic cases so far. It is highly fatal zoonotic disease caused by bite of infected tick. The objective of our study is to describe clinical features, treatment and outcome of CCHF positive cases during its outbreak in Hazara division, with the intention to bring focus to this fatal emerging disease.
Methods:
This study was conducted in Medical A Unit of Ayub Teaching Hospital, Abbottabad for a period of three months. All patients presenting with fever and platelet count less than 50,000/mm3 were included in the study. Apart from baseline investigations their blood samples were sent for the detection of CCHF virus. All patients were given supportive treatment including fresh frozen plasma and were started on oral Ribavirin. All patients were isolated and barrier personal precautions were observed by health care givers.
Results:
Eighty-eight patients with fever and thrombocytopenia were included. Among these, 8 were found to be positive for CCHF. Supportive treatment with oral Ribavirin was given to all patients. One patient with CCHF died. One left against advice and six patients recovered completely.
Conclusions:
All patients presenting with acute fever and thrombocytopenia should be suspected and evaluated for CCHF. Oral Ribavirin is safe and effective in the treatment of CCHF.
Related Concept Videos
Hepatitis
Hazard Ratio
For example, in a clinical trial...
Cytomegalovirus Disease
Sexually Transmitted Infections
Infectious Diseases and Their Occurrence
Arboviral Encephalitis

